July 2026 Research Update

Across these papers, the overall message is that finding Fabry disease earlier often depends on where you look (such as high-risk clinics) and on what you do after one person is diagnosed (testing relatives). At the same time, genetic results can be complicated: many people have gene changes that do not clearly mean Fabry disease, so follow-up beyond a single test result remains important. [1] [2] [3]

In a multicenter study from Spain of 260 high-risk individuals, GLA gene variants were found in 127 people (48.8%), including 10 variants the authors had not seen reported before. The study also noted organ involvement among people carrying variants, but emphasized that a genetic finding by itself does not prove a Fabry diagnosis or determine treatment decisions, highlighting the need for long-term tracking of how specific variants relate to symptoms. [1]

In a multicenter screening study of 1,359 adults on hemodialysis in Turkiye, 12 people (0.88%) had GLA variants, but only one person had a confirmed classic Fabry disease-causing variant (0.07%). Most detected variants were benign or likely benign, including several described as pseudodeficiency alleles, and the authors reported confirmatory testing with enzyme activity and a blood marker (lyso-Gb3). [2]

A multigenerational family case series showed how cascade genetic screening (testing relatives after one diagnosis) can reduce delays and identify Fabry disease earlier in life, including diagnosing an infant at 6 months. The report also highlighted that symptoms and organ involvement can vary widely even within the same family. [3]

For patients and caregivers, this set of studies mainly provides background on how Fabry disease is being looked for in real-world settings and why results can be hard to interpret. It underlines two realities at once: targeted screening can uncover potential cases, but many gene changes need careful interpretation over time; and when one person is confirmed, family testing can efficiently find other affected relatives. What remains uncertain is how best to classify and follow people with gene variants that are not clearly disease-causing, which is why the papers emphasize registries and longer follow-up.

These case reports highlight how Fabry disease can present in ways that resemble more common heart conditions, leading to delays, and how rare heart and blood vessel findings in infants can trigger broader genetic testing. Because each paper describes only one patient, they cannot show how often these patterns occur, but they show why clinicians sometimes need Fabry-specific testing when typical explanations do not fully fit. [4] [5]

In a 60-year-old man, Fabry disease was confirmed after a 15-year delay during which he was first labeled as having coronary artery disease and later hypertrophic cardiomyopathy (heart muscle thickening). Diagnosis was supported by low alpha-galactosidase A enzyme activity and GLA gene sequencing, along with heart imaging showing thickening of both ventricles and scar patterns the authors considered suggestive of Fabry. [4]

In a 7-month-old infant with giant coronary artery aneurysms and clotting inside the aneurysms, the initial working diagnosis was atypical Kawasaki disease, but genetic testing later identified a GLA mutation and low alpha-galactosidase A enzyme activity consistent with Fabry disease. The authors stated that this single case cannot prove that Fabry disease caused the coronary aneurysms, but it illustrates a diagnostic challenge when severe inflammation-like blood vessel findings occur. [5]

For patients, this theme is most relevant as context for why some people, especially those with mainly heart involvement, may experience long diagnostic journeys, and why genetic and enzyme testing sometimes enters the picture after other diagnoses have been considered. These reports also show that very rare presentations can lead to questions about whether Fabry is contributing, but single cases cannot answer cause-and-effect. Larger studies would be needed to learn how common these scenarios are and which signs most reliably point toward Fabry disease.

This group of studies looked at different ways to monitor Fabry disease using measurable markers in blood, skin, or urine. Overall, the results suggest that some markers can reflect specific aspects of Fabry disease (such as pain, heart structure changes, or overall severity scores), but no single marker consistently matched all organ involvement or brain imaging changes. Most of the evidence here is exploratory (small studies, often cross-sectional), so how well these markers predict future problems remains uncertain. [6] [7] [8] [9] [10]

In a moderate-sized clinical study using automated analysis of skin punch biopsies, dermal Gb3 (a stored fat-like substance) was higher in adults with disease-causing GLA variants than in controls, and the test showed moderate accuracy for identifying Fabry disease. However, dermal Gb3 did not track with overall disease severity scores or with the amount of white matter changes seen on brain MRI, and long-term treatment did not consistently change the dermal Gb3 level. Among men with Fabry disease, higher dermal Gb3 was linked to Fabry-associated pain. [6]

In a small, retrospective 12-month study, higher blood lyso-Gb3 levels went along with higher scores on two Fabry severity scales (MSSI and DS3), but not with a third scale (FASTEX). Over 12 months, both lyso-Gb3 and the MSSI and DS3 scores decreased, but the authors described the analyses as exploratory because only 18 adults were included and correlations were stronger in men. [7]

In a very small single-center study of 14 related adults with the same GLA variant, the blood marker VCAM-1 was much higher in Fabry patients than in matched controls. Within the Fabry group, higher VCAM-1 was linked to signs of early heart remodeling on imaging and to longer symptom duration, while another marker (IL-6) was also higher and syndecan-1 was not. Because this was cross-sectional and from one family, it cannot show whether VCAM-1 predicts who will develop later heart disease. [8]

Another small clinical cohort study examined markers related to mitochondrial stress (Hsp60 in blood cells, and the circulating markers FGF-21 and GDF-15). The relationships differed by sex: higher Hsp60 linked to lower heart muscle mass and better kidney function in men in certain subgroups, but to higher heart muscle mass and greater severity in women, and GDF-15 was higher in men than controls. Both circulating markers were related to age and severity, suggesting they may reflect one pathway that contributes to why Fabry disease can look different from person to person. [9]

One lab-based study focused on urinary mulberry bodies, which can be seen in urine in Fabry disease. Using advanced imaging and cell models, the authors concluded these structures likely come from podocytes (specialized kidney cells) and are mainly made of lysosome-derived material, and they identified components that are also found in the kidney's filtration barrier. In GLA knockout cells, Gb3 buildup was linked to JNK-related cell death, connecting this urinary structure to possible kidney injury mechanisms, but this was not a clinical outcomes study. [10]

For patients and caregivers, these studies support the idea that monitoring in Fabry disease may involve multiple types of information, because different markers appear to reflect different parts of the condition (for example, pain in some men, certain heart imaging changes, or overall severity scores). Right now, much of this evidence is early-stage, so it is still unclear which markers (alone or in combination) best track day-to-day disease activity or predict future organ problems across diverse Fabry populations. Some work is also basic science (urine structures and cell models), which mainly helps explain possible kidney disease pathways rather than directly changing current monitoring. [6] [7] [8] [9] [10]

Taken together, these papers suggest that Fabry disease can affect both heart muscle and the heart's electrical system, sometimes in ways that are not obvious on a routine test. A broader, multi-test approach (heart tracing, blood markers, ultrasound, and heart MRI) was repeatedly highlighted as a way to better describe heart involvement and follow changes over time, but some proposed approaches still need validation. [11]

In a cross-sectional study of 62 people with Fabry disease compared with 45 healthy controls, several electrocardiogram (ECG) measurements shifted as heart disease progressed. The Tp-e/QT measure decreased and an ECG voltage measure (Sokolow-Lyon index) increased with progression, and QRS width and Tp-e/QT were linked to the severity of heart involvement defined by ultrasound and heart MRI done the same day. [12]

One case report described a 72-year-old woman with Fabry disease whose rhythm symptoms were tied to advanced interatrial block (a problem with electrical conduction between the upper heart chambers) that was clearer on a P-wave focused ambulatory monitor than on routine testing. Despite starting enzyme replacement therapy, she later developed atrial fibrillation and her heart MRI showed patchy scarring-like changes in the left ventricle, while left atrial size stayed normal. [13]

Another case report described a 70-year-old man with thickened heart muscle and multiple heart-related conditions whose changing ECG patterns led to heart MRI and genetic testing, confirming late-onset Fabry disease (GLA p.N215S). He started enzyme replacement therapy and had a defibrillator implanted for primary prevention, remained clinically stable for 2 years, and later died from worsening heart failure and severe comorbidities. [14]

For patients and caregivers, this set of papers mainly adds context on how Fabry disease can show up in the heart: electrical conduction changes, atrial rhythm problems like atrial fibrillation, and changes on heart imaging can occur together or evolve over time. The expert pathway and the ECG study support the idea that combining several kinds of heart information may better reflect disease severity than relying on a single test, but the proposed framework is not yet proven and the case reports describe single individuals, so results may not apply to everyone. [11] [12] [13] [14]

Across these papers, kidney outcomes in Fabry disease looked strongly tied to how advanced kidney involvement was when treatment decisions were made. In small case series, enzyme replacement therapy was linked to lower disease-related blood markers and sometimes lower protein in the urine, but it did not always prevent progression to kidney failure. An expert perspective emphasized that clinicians still face gaps in evidence-based criteria when deciding when and how to treat and monitor Fabry-related kidney disease. [15] [16] [17]

In a two-person case series of Chinese adult men with classic Fabry disease and protein in the urine, agalsidase beta was well tolerated and lowered the disease activity marker Lyso-Gb3 by about two-thirds in both patients. One patient progressed to kidney transplantation after 21 months on enzyme replacement, while the other stayed on long-term enzyme replacement with a partial reduction in 24-hour urine protein. Both patients also used medicines aimed at reducing protein in the urine. [15]

In a six-patient case series from Tunisia (three families), most patients had protein in the urine and some had early high filtration, while two progressed to end-stage kidney disease. The authors reported that earlier enzyme replacement therapy was linked to preserved kidney function and reduced protein in the urine over time, whereas delayed treatment was linked to progression to kidney failure in at least one patient. Kidney biopsy, when available, showed kidney cell changes consistent with Fabry kidney involvement. [16]

A nephrologist-authored expert article described practical challenges in diagnosing Fabry-related kidney disease and making treatment decisions, highlighting that there are limited solid, evidence-based criteria for predicting outcomes and choosing therapies. The article provides guidance for management and monitoring, but its conclusions reflect expert opinion rather than results from a controlled trial. [17]

For patients and caregivers, these papers mainly add context for why kidney-related decisions in Fabry disease can differ from person to person, especially when protein in the urine or reduced kidney function is already present. The clinical evidence here comes from small case series and an expert-opinion guide, so it can describe real-world patterns but cannot reliably predict what will happen for any individual. What remains uncertain is which specific test results or disease stages best identify who will have kidney stability on enzyme replacement alone versus who will still progress to dialysis or transplant.

Across the papers this month, research looked beyond the heart and kidneys to symptoms involving the ears, balance system, and brain-related control of eye movements. The overall pattern was that people may have symptoms even when standard tests look normal, and some differences may be subtle and not easily predicted from typical clinical or genetic information. [18]

In a cross-sectional study of 24 people with Fabry disease, just over half reported ear-related symptoms, but most still had normal hearing thresholds on standard hearing tests. The most notable abnormality was slower-than-expected eye-movement reaction time (prolonged saccadic latency), which can reflect changes in how the brain and nerves coordinate quick eye movements. [18]

When balance function was tested using a head-impulse method, semicircular canal function was mostly preserved, but abnormalities were seen most often in the lateral canal compared with the other canals. The study did not find clear links between these neuro-otologic test results and clinical features or genetic variables. [18]

For patients and caregivers, this is mainly background research that helps describe how Fabry disease can affect hearing, balance, and eye-movement control in ways that may not be obvious from routine hearing tests alone. Because this was a single, small snapshot in time, it cannot show how these findings change over time or how well they predict day-to-day symptoms. It also remains unclear why some people have symptoms with normal test results, and which tests are most useful in different situations. [18]

This month also included laboratory research exploring how Fabry-related lipid storage might affect the brain, focusing on the hippocampus, a region important for memory. In an animal model, researchers connected where the stored lipid collected to performance on a spatial learning task, but this type of work cannot directly tell how often or how severely people may be affected. [19]

In alpha-Gal A knockout mice, the stored lipid Gb3 was increased in the hippocampus, especially in blood vessel lining cells and within capillary spaces, and it was also detected in certain neurons in the dentate gyrus region. Gb3 did not overlap with markers of astrocytes or microglia, although these support and immune cells were often located near Gb3-positive vessels. [19]

On a standard water-maze test, the knockout mice learned the platform location less well and showed worse spatial memory on the probe trial compared with control mice. The differences were not explained by slower swimming speed or shorter swim distance. [19]

For patients, this mouse study is early-stage research that helps scientists explore possible biological reasons for learning or memory issues, but it does not show that the same pattern necessarily happens in people. The results point to the hippocampus and brain blood vessels as potential areas of interest, yet it remains uncertain how Gb3 storage in these locations relates to real-world thinking, memory, or attention symptoms in Fabry disease. More clinical research would be needed to understand whether similar changes occur in humans and how they relate to everyday function. [19]

Across this group of papers, researchers focused on tools that can make Fabry disease research more precise: (1) modeling how a medicine moves through the body in people with different kidney function, and (2) building patient-derived cell models to study specific genetic variants in the lab. Together, these studies aim to reduce uncertainty in future trials by improving dosing assumptions and by providing standardized lab models, but they do not by themselves show changes in symptoms or long-term outcomes.

In a population pharmacokinetic modeling analysis using data from 250 participants across multiple Phase 1 and Phase 3 studies, lucerastat clearance decreased as estimated kidney function (eGFR) decreased, meaning the body removed the drug more slowly when kidney function was lower. [20] Dose adaptation for reduced kidney function, as used in Phase 3, was reported to lead to similar overall drug exposure across different levels of kidney impairment. [20]

The same modeling work suggested body weight and having Fabry disease versus not having it had only limited impact on lucerastat clearance and distribution compared with kidney function. [20] This supports the idea that kidney function was the main factor considered when trying to make drug exposure more comparable between participants. [20]

Two exploratory lab studies created human induced pluripotent stem cell (hiPSC) lines from Fabry disease patients with specific GLA variants, which can be used to study mechanisms and test approaches in a controlled setting. One line came from a 64-year-old man with the GLA p.A143T variant (AOUMEYi005-A). [21] Another line came from a female patient with a GLA c.644A>G missense mutation (MHHi040-A) and showed typical stem cell features, including normal chromosomes and the ability to form multiple cell types. [22]

For patients and caregivers, this set of studies is mainly background research that supports how future Fabry studies may be designed. The lucerastat modeling work highlights that kidney function can meaningfully change drug levels and that adjusting for kidney function can make exposure more consistent within clinical studies, but it does not report symptom improvement or organ outcomes. The new patient-derived stem cell lines are lab resources (not treatments) that may help researchers test ideas for specific GLA variants, but it remains uncertain how quickly these models will translate into new or improved therapies.

Across a large, real-world US dataset from 2020 to 2024, people with lysosomal storage disorders as a group had higher odds of being hospitalized with COVID-19 than matched controls, but not every disorder contributed equally to that pattern. After taking other factors into account, Fabry disease did not show a clear increase in hospitalization risk in this analysis, and survival among hospitalized patients was similar to controls. [23]

In this retrospective cohort study using nationwide harmonized electronic health records, the overall lysosomal storage disorder group had higher odds of COVID-19 hospitalization than controls (odds ratio 1.86). When the researchers adjusted for other factors, certain neurodegenerative lysosomal storage disorders still showed higher hospitalization odds, while Fabry disease (and Gaucher disease) was not statistically significant after adjustment. [23]

Among people who were hospitalized with COVID-19, mortality looked similar between lysosomal storage disorder patients and controls, with nearly identical one-year survival (82.1% vs 82.0%). This suggests that, in this dataset, the main difference was in the chance of being hospitalized rather than survival after hospitalization. [23]

For Fabry patients and caregivers, this study mainly provides background, population-level context: it does not show a clear signal that Fabry disease itself increased the chance of COVID-19 hospitalization once other health factors were considered, and it did not show worse survival among those hospitalized. What remains uncertain is how well electronic health record analyses capture individual differences in Fabry severity, organ involvement, and treatments, and whether results would look the same in other healthcare systems or specific Fabry subgroups. [23]